The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes two weeks after J&J ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Dividend growth stocks offer a balance of stability and compounding returns, and here are three standout companies with ...
( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...
Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...